DDInter392 DDInter1763
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Cladribine {u} (Compound) downregulates {v} (Gene) MYC
MYC {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Cladribine {u} (Compound) upregulates {v} (Gene) LRP10
LRP10 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Cladribine {u} (Compound) binds {v} (Gene) POLE2
POLE2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Cladribine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Cladribine {u} (Compound) upregulates {v} (Gene) DUSP14
DUSP14 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Cladribine {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Febrile neutropenia {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Cladribine {u} (Compound) downregulates {v} (Gene) MYC
MYC {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Cladribine {u} (Compound) upregulates {v} (Gene) LRP10
LRP10 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Cladribine may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Cladribine (Compound) downregulates MYC (Gene) and MYC (Gene) is upregulated by Temsirolimus (Compound)
Cladribine (Compound) upregulates LRP10 (Gene) and LRP10 (Gene) is upregulated by Temsirolimus (Compound)
Cladribine (Compound) binds POLE2 (Gene) and POLE2 (Gene) is downregulated by Temsirolimus (Compound)
Cladribine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is downregulated by Temsirolimus (Compound)
Cladribine (Compound) upregulates DUSP14 (Gene) and DUSP14 (Gene) is downregulated by Temsirolimus (Compound)
Cladribine (Compound) causes Febrile neutropenia (Side Effect) and Febrile neutropenia (Side Effect) is caused by Temsirolimus (Compound)
Cladribine may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Cladribine (Compound) downregulates MYC (Gene) and MYC (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)
Cladribine (Compound) upregulates LRP10 (Gene) and LRP10 (Gene) is downregulated by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)